LCE2A Inhibitors
LCE2A inhibitors are chemical entities that suppress the activity of LCE2A through the modulation of specific cellular pathways essential for keratinocyte differentiation and skin barrier function, in which LCE2A plays an integral role. Compounds like PD 98059 and U0126, which are MEK inhibitors, abate the MAPK/ERK pathway, leading to potentially diminished LCE2A activity, as this pathway is implicated in keratinocyte differentiation-a process central to LCE2A function. Similarly, LY 294002, a PI3K inhibitor, and H-89, a PKA inhibitor, could reduce LCE2A activity by interfering with the PI3K/AKT and cAMP-dependent signaling pathways, respectively, which are known to regulate keratinocyte proliferation and differentiation. Rottlerin and Calphostin C, both of which inhibit different isoforms of protein kinase C, could lead to decreased LCE2A activity by altering signaling mechanisms involved in skin cell differentiation.
Furthermore, LCE2A's involvement in the development and maintenance of the skin barrier suggests that lipid signaling pathways could be key targets for its inhibition. GW4869, which targets Sphingosine Kinase 1, may diminish the levels of signaling molecules like sphingosine-1-phosphate and ceramide, potentially leading to reduced LCE2A activity. 4-Hydroxyphenylretinamide, by modulating retinoid signaling, could perturb keratinocyte differentiation and thus LCE2A activity. Additionally, D609 and Manumycin A, which inhibit phosphatidylcholine-specific phospholipase C and farnesyltransferase respectively, could lead to altered cellular signaling affecting LCE2A's function in skin cells. By impacting various facets of keratinocyte function, these inhibitors collectively contribute to the suppression of LCE2A activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
GW4869 is a neutral sphingomyelinase inhibitor that could lead to decreased ceramide levels, indirectly reducing signaling pathways that may involve LCE2A function related to skin barrier formation and repair mechanisms. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor that can alter MAPK/ERK pathway activity, which is involved in keratinocyte proliferation and differentiation, processes where LCE2A is implicated, thus potentially diminishing LCE2A activity. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Manumycin A, an farnesyltransferase inhibitor, could indirectly diminish LCE2A activity by disrupting prenylation and subsequent signaling events in skin cell differentiation where LCE2A may play a role. | ||||||
D609 | 83373-60-8 | sc-201403 sc-201403A | 5 mg 25 mg | $189.00 $575.00 | 7 | |
D609 is a phosphatidylcholine-specific phospholipase C inhibitor that could indirectly inhibit LCE2A by altering phospholipid-derived signaling molecules involved in skin cell proliferation and differentiation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002, a PI3K inhibitor, may lead to reduced AKT signaling, potentially diminishing LCE2A activity since the PI3K/AKT pathway is involved in keratinocyte survival and differentiation. | ||||||
Rottlerin | 82-08-6 | sc-3550 sc-3550B sc-3550A sc-3550C sc-3550D sc-3550E | 10 mg 25 mg 50 mg 1 g 5 g 20 g | $84.00 $166.00 $302.00 $2091.00 $5212.00 $16657.00 | 51 | |
Rottlerin, a selective PKC delta inhibitor, could indirectly diminish LCE2A activity by modifying keratinocyte differentiation pathways, where LCE2A is expressed. | ||||||
4-Hydroxyphenylretinamide | 65646-68-6 | sc-200900 sc-200900A | 5 mg 25 mg | $104.00 $315.00 | ||
4-Hydroxyphenylretinamide, a synthetic retinoid, could lead to altered differentiation of keratinocytes and potentially decrease LCE2A activity through modification of retinoid signaling that influences skin cell differentiation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, an inhibitor of MEK1/2, could diminish LCE2A activity by interfering with the MAPK/ERK pathway, which plays a role in the regulation of keratinocyte proliferation and differentiation where LCE2A is involved. | ||||||
Cerulenin (synthetic) | 17397-89-6 | sc-200827 sc-200827A sc-200827B | 5 mg 10 mg 50 mg | $161.00 $312.00 $1210.00 | 9 | |
Cerulenin, a fatty acid synthase inhibitor, could indirectly inhibit LCE2A activity by reducing lipid synthesis that is crucial for skin barrier function and potentially impacting pathways where LCE2A is implicated. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $343.00 $1642.00 | 20 | |
Calphostin C, a PKC inhibitor, could lead to diminished LCE2A activity by affecting the protein kinase C pathway, known to be involved in keratinocyte differentiation and function where LCE2A plays a role. | ||||||